More Generic Suits Cite Brands Blocking Bioequivalency Studies

Accord Healthcare and Intas Pharmaceuticals are the latest generic drugmakers resorting to litigation to force a brand company to provide drug samples for bioequivalence testing. A suit filed April 1 in U.S. District Court for the Southern District of Florida argues Acorda Therapeutics and distributor H.D. Smith violated antitrust laws when they denied samples of multiple sclerosis drug Ampyra (dalfampridine).
Washington Drug Letter